Presenting at Life Science Conference in New York and at Bio-Business
Seminar in Zürich
(Thomson Reuters ONE) - (Oslo 18 September, 2009): Biotec Pharmacon has been invited topresent at USB Investment Bank's Global Life Science Conference inNew York on September 23rd and at the 5th Swiss-ScandinavianBio-Business Seminar in Zürich on October 1st.The presentations will be held by Sven Rohmann, VP BusinessDevelopment in Biotec Pharmacon. The presentation slides will be madeavailable on the company's web site www.biotec.no as from the date ofpresenting.For further information, please contact:CEO Lars Viksmoen, tel: +47 40620870VP Sven Rohmann, tel: +41 79 577 8895About Biotec Pharmacon:The biopharmaceutical company Biotec Pharmacon developspharmaceutical products for prevention and treatment of immunerelated diseases. The company has developed the bioactive substanceSBG (soluble beta glucan), which is in clinical phase III for twoindications; treatment of diabetic ulcers and prevention andtreatment of oral mucositis. The company's clinical developmentprogram also includes immune therapy of cancer, where combinationtreatments with SBG and monoclonal antibodies are being studied inclinical phase I/II. In addition, the company is involved in severalpreclinical studies with SBG. Biotec Pharmacon also produces andmarkets non-pharmaceutical health- and diagnostic products and owns100% of Immunocorp Consumer Health AS and the marine enzyme companyBiotec Marine Biochemicals AS.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 18.09.2009 - 09:02 Uhr
Sprache: Deutsch
News-ID 5954
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 291 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Presenting at Life Science Conference in New York and at Bio-Business
Seminar in Zürich"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotec Pharmacon ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
